Nexalin Technology, Inc. (NASDAQ:NXL – Get Free Report) was the target of a large increase in short interest in October. As of October 30th, there was short interest totaling 12,581 shares, an increase of 180.7% from the October 15th total of 4,482 shares. Based on an average trading volume of 59,806 shares, the short-interest ratio is currently 0.2 days. Approximately 2.1% of the company’s stock are sold short.
Nexalin Technology Stock Performance
Shares of NXL traded down $0.01 during trading hours on Friday, hitting $1.48. 16,514 shares of the company were exchanged, compared to its average volume of 43,064. The company has a market cap of $1.08 million, a PE ratio of -0.11 and a beta of 4.31. The firm’s 50 day moving average is $3.34 and its 200-day moving average is $10.10. Nexalin Technology has a 52 week low of $1.31 and a 52 week high of $35.53.
Nexalin Technology (NASDAQ:NXL – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($3.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.91) by ($0.52). Nexalin Technology had a negative net margin of 3,384.12% and a negative return on equity of 344.93%. The company had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.07 million. As a group, equities analysts forecast that Nexalin Technology will post -11.42 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities analysts have recently weighed in on NXL shares. Weiss Ratings downgraded shares of Nexalin Technology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, September 25th. Zacks Research raised Nexalin Technology to a “hold” rating in a research report on Thursday, October 1st. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Nexalin Technology currently has a consensus rating of “Reduce”.
Read Our Latest Analysis on NXL
Hedge Funds Weigh In On Nexalin Technology
A hedge fund recently bought a new position in Nexalin Technology stock. PEAK6 LLC acquired a new position in Nexalin Technology, Inc. (NASDAQ:NXL – Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 240,210 shares of the company’s stock, valued at approximately $79,000. PEAK6 LLC owned about 1.09% of Nexalin Technology at the end of the most recent quarter. Institutional investors and hedge funds own 0.65% of the company’s stock.
Nexalin Technology Company Profile
Nexalin Technology, Inc. (NASDAQ:NXL) is a medical technology company focused on developing and commercializing noninvasive neurostimulation devices for mental health and neurological applications. Its technology is designed to deliver low-intensity electrical stimulation to the brain with the goal of influencing neural activity associated with conditions such as depression, anxiety, insomnia, post-traumatic stress disorder and substance-use disorders. The company’s product portfolio includes the Gen-2 and Gen-3 neurostimulation systems.
See Also
- Five stocks we like better than Nexalin Technology
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Nexalin Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexalin Technology and related companies with MarketBeat.com's FREE daily email newsletter.
